King Charles III to Visit Australia and Samoa as He Recovers from Cancer

 Britain's King Charles III (R) meets British actor Idris Elba and young people during an event for The King's Trust to discuss youth opportunities, at St James's Palace in central London on July 12, 2024. (AFP)
Britain's King Charles III (R) meets British actor Idris Elba and young people during an event for The King's Trust to discuss youth opportunities, at St James's Palace in central London on July 12, 2024. (AFP)
TT

King Charles III to Visit Australia and Samoa as He Recovers from Cancer

 Britain's King Charles III (R) meets British actor Idris Elba and young people during an event for The King's Trust to discuss youth opportunities, at St James's Palace in central London on July 12, 2024. (AFP)
Britain's King Charles III (R) meets British actor Idris Elba and young people during an event for The King's Trust to discuss youth opportunities, at St James's Palace in central London on July 12, 2024. (AFP)

King Charles III is preparing to visit Australia and Samoa in October, an itinerary that will span 12 time zones and test the monarch’s stamina as he recovers from cancer treatment.

The trip, announced on Sunday by Buckingham Palace, marks a watershed moment for the 75-year-old king, who has been slowly returning to public duties after taking a break following his cancer diagnosis in early February. The decision to undertake such a long journey will be seen as a sign of Charles’ recovery, even though the program in Australia will be “limited.”

The visit to Australia will be a critical moment for the king as he tries to shore up support for the monarchy at home and abroad. The trip will mark the first time since he ascended the throne that Charles will visit one of the 14 countries outside the United Kingdom where the British monarch remains head of state, a link that is a source of pride for some but an unwelcome reminder of Britain’s colonial dominance for others.

While he will undoubtedly be welcomed by fans waving the flag and singing “God Save the King,” Charles is also likely to hear anti-monarchy voices in a country where 45% of voters in a 1999 referendum supported creating an Australian republic. Prime Minister Anthony Albanese’s Labour Party supports ditching the monarchy, but the government says it isn’t a priority and there is “no timeline” for another referendum.

“It’s clear that there’s a real re-evaluation going on there as to whether the Commonwealth, and certainly the realms, want to retain their connection to the British monarchy or not,” Ed Owens, a historian and author of “After Elizabeth: Can the Monarchy Save Itself?” told The Associated Press in an interview before the trip was announced. “So, you know, there are troubled waters ahead.”

The palace provided few details of the tour. Charles and Queen Camilla will visit the Australian Capital Territory and New South Wales as well as making a more formal state visit to Samoa, where the king will appear at the Commonwealth Heads of Government Meeting, the palace said.

The capital territory is home to Canberra, Australia’s national capital. Sydney, Australia’s largest city, is in New South Wales.

Charles holds the symbolic title of head of the Commonwealth, a voluntary association of 56 independent nations, most of which have historic ties to Britain. The annual heads of government meeting will be held Oct. 21-25.

However, the trip will not include a stop in New Zealand.

“The King’s doctors have advised that a further extension to Their Majesties’ trip should be avoided at this time, to prioritize His Majesty’s continued recovery,” the palace said in a statement.

The trip comes at a time when the health problems of Charles and Kate, the Princess of Wales, have highlighted the challenges faced by a slimmed-down royal family as the king pledges to cut costs.

With fewer working royals available to carry out the endless round of ribbon cuttings, awards ceremonies and state events that make up the life of a modern royal, the remaining family members have been forced to take on more events.

Charles’ cancer diagnosis occurred at the same time that the Princess of Wales — one of the most popular royals — underwent abdominal surgery and later announced she, too, had cancer. Prince William took time off to support his wife and their young family.

That left Queen Camilla, the king’s sister, Princess Anne, and his younger brother, Prince Edward, to shoulder the load. Princess Anne was briefly hospitalized last month after an accident thought to involve a horse left her with a concussion.



Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
TT

Weight-Loss Drugs May Lower Cancer Risk in People with Diabetes, a Study Suggests 

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. (Reuters) 

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in US adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss.

This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity.

“This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,” said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study.

The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University’s Grossman School of Medicine.

“Chronic disease and chronic disease prevention are some of my passions,” said Mavromatis, a former research fellow with an NIH training program.

GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain.

In the study, researchers analyzed data from 43 US health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.

The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.